PFIZER INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
PFIZER INC (PFE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $0 for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2026-08-04
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2026-06-28 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2026-03-29 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-06-29 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-03-30 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2025 was $1.27B.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2024 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|
| 2026-06-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | |
| 2026-03-29 | $0.00 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | $1.27B 10-K · filed 2026-02-26 | ||
| 2025-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | |
| 2025-03-30 | $0.00 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |